› Forums › General Melanoma Community › XL 184 clinical trial
- This topic has 12 replies, 3 voices, and was last updated 12 years, 10 months ago by kylez.
- Post
-
- March 2, 2012 at 3:27 am
Hi,
I just wanted to mention this trial as my melanoma Dr. brought it up at our last meeting.
I don't think I've seen this one on the bulletin board.
http://clinicaltrials.gov/ct2/show/study/NCT00940225#locn
Julie in las Vegas
Hi,
I just wanted to mention this trial as my melanoma Dr. brought it up at our last meeting.
I don't think I've seen this one on the bulletin board.
http://clinicaltrials.gov/ct2/show/study/NCT00940225#locn
Julie in las Vegas
- Replies
-
-
- March 2, 2012 at 6:27 pm
Julie,
XL184, is a potent dual inhibitor of the MET and VEGF pathways designed to block MET driven tumor escape.
Are you Braf or Nras Positive?
Jimmy B
-
- March 2, 2012 at 9:00 pm
You may want look into a clinical trials with a PI3K/Akt/mTOR Inhibitors. You want to stop and kill the tumor cell growth.
-
- March 2, 2012 at 9:00 pm
You may want look into a clinical trials with a PI3K/Akt/mTOR Inhibitors. You want to stop and kill the tumor cell growth.
-
- March 2, 2012 at 9:00 pm
You may want look into a clinical trials with a PI3K/Akt/mTOR Inhibitors. You want to stop and kill the tumor cell growth.
-
- March 2, 2012 at 6:27 pm
Julie,
XL184, is a potent dual inhibitor of the MET and VEGF pathways designed to block MET driven tumor escape.
Are you Braf or Nras Positive?
Jimmy B
-
- March 2, 2012 at 6:27 pm
Julie,
XL184, is a potent dual inhibitor of the MET and VEGF pathways designed to block MET driven tumor escape.
Are you Braf or Nras Positive?
Jimmy B
-
- You must be logged in to reply to this topic.